Stockreport

Immunome Recognizes Ayala Pharmaceuticals' Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors [Yahoo! Finance]

Immunome, Inc.  (IMNM) 
PDF BOTHELL, Wash., February 20, 2024 BUSINESS WIRE Immunome , Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targete [Read more]